Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT01371799 | A Study to Examine the Pharmacodynamic Effects of GSK1034702 on Neurophysiological Biomarkers of Cognition in Nicotine Abstained Otherwise Healthy Smokers | PHASE1 | COMPLETED | 9 | — | — | Dec 17, 2009 | Jun 18, 2010 | Jun 14, 2017 | 1 | United Kingdom |
To investigate the effects of GSK1034702 on the mismatch negativity neurophysiologic marker of cognition.
| Arm | Type | Description |
|---|---|---|
| Study drug at 4mg | EXPERIMENTAL | GSK1034702 at 4mg |
| Study drug at 8mg | EXPERIMENTAL | GSK1034702 at 8mg |
| Placebo | PLACEBO_COMPARATOR | Placebo |
| Name | Type | Description |
|---|---|---|
| Drug | DRUG | Placebo |
Inclusion Criteria A subject will be eligible for inclusion in this study only if all of the following criteria apply: * Otherwise healthy smokers as determined by a responsible physician, based on a medical evaluation including own and familial medical history, physical examination, psychiatric hi...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Teladoc Health, Inc. | TDOC | 1 | NA | Undisclosed |
| Unity Health Toronto | UBX | 2 | NA | Undisclosed |